iHuman (NYSE:IH - Get Free Report)'s stock had its "hold (c+)" rating restated by analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
iHuman Stock Down 3.0%
NYSE:IH opened at $2.94 on Wednesday. The company has a market capitalization of $150.97 million, a PE ratio of 10.14 and a beta of 0.40. iHuman has a 52-week low of $1.47 and a 52-week high of $3.60. The stock has a fifty day simple moving average of $2.84 and a 200-day simple moving average of $2.50.
iHuman (NYSE:IH - Get Free Report) last released its quarterly earnings results on Thursday, September 18th. The company reported $0.08 earnings per share (EPS) for the quarter. The business had revenue of $27.94 million during the quarter. iHuman had a return on equity of 11.59% and a net margin of 12.46%.
Institutional Trading of iHuman
An institutional investor recently bought a new position in iHuman stock. Virtu Financial LLC acquired a new position in shares of iHuman Inc. Sponsored ADR (NYSE:IH - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,150 shares of the company's stock, valued at approximately $26,000. 4.92% of the stock is owned by hedge funds and other institutional investors.
iHuman Company Profile
(
Get Free Report)
iHuman Inc provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iHuman, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iHuman wasn't on the list.
While iHuman currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.